These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 23795862)

  • 21. Effect of aripiprazole on cognition in the treatment of patients with schizophrenia.
    Riedel M; Spellmann I; Schennach-Wolff R; Musil R; Dehning S; Cerovecki A; Opgen-Rhein M; Matz J; Seemüller F; Obermeier M; Severus E; Engel RR; Müller N; Möller HJ
    Pharmacopsychiatry; 2010 Mar; 43(2):50-7. PubMed ID: 20336597
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effectiveness of switching from aripiprazole to ziprasidone in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Bae KY; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2010 May; 33(3):121-5. PubMed ID: 20502130
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immediate versus gradual suspension of previous treatments during switch to aripiprazole: results of a randomized, open label study.
    Pae CU; Serretti A; Chiesa A; Mandelli L; Lee C; Lee C; Kim J; De Ronchi D; Paik IH
    Eur Neuropsychopharmacol; 2009 Aug; 19(8):562-70. PubMed ID: 19442491
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial.
    Shim JC; Shin JG; Kelly DL; Jung DU; Seo YS; Liu KH; Shon JH; Conley RR
    Am J Psychiatry; 2007 Sep; 164(9):1404-10. PubMed ID: 17728426
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A 12-week randomized, open-label study of perospirone versus aripiprazole in the treatment of Japanese schizophrenia patients.
    Takekita Y; Kato M; Wakeno M; Sakai S; Suwa A; Nishida K; Okugawa G; Kinoshita T
    Prog Neuropsychopharmacol Biol Psychiatry; 2013 Jan; 40():110-4. PubMed ID: 23022672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intramuscular aripiprazole in the acute management of psychomotor agitation.
    De Filippis S; Cuomo I; Lionetto L; Janiri D; Simmaco M; Caloro M; De Persis S; Piazzi G; Simonetti A; Telesforo CL; Sciarretta A; Caccia F; Gentile G; Kotzalidis GD; Girardi P
    Pharmacotherapy; 2013 Jun; 33(6):603-14. PubMed ID: 23505124
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aripiprazole augmentation in the management of residual symptoms in clozapine-treated outpatients with chronic schizophrenia: An open-label pilot study.
    Mitsonis CI; Dimopoulos NP; Mitropoulos PA; Kararizou EG; Katsa AN; Tsakiris FE; Katsanou MN
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Mar; 31(2):373-7. PubMed ID: 17092620
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol.
    Andrezina R; Josiassen RC; Marcus RN; Oren DA; Manos G; Stock E; Carson WH; Iwamoto T
    Psychopharmacology (Berl); 2006 Oct; 188(3):281-92. PubMed ID: 16953381
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of risperidone and aripiprazole on neurocognitive rehabilitation for schizophrenia.
    Matsuda Y; Sato S; Iwata K; Furukawa S; Hatsuse N; Watanabe Y; Anzai N; Kishimoto T; Ikebuchi E
    Psychiatry Clin Neurosci; 2014 Jun; 68(6):425-31. PubMed ID: 24506576
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA).
    Tandon R; Marcus RN; Stock EG; Riera LC; Kostic D; Pans M; McQuade RD; Nyilas M; Iwamoto T; Crandall DT
    Schizophr Res; 2006 May; 84(1):77-89. PubMed ID: 16483745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of aripiprazole against hostility in schizophrenia and schizoaffective disorder: data from 5 double-blind studies.
    Volavka J; Czobor P; Citrome L; McQuade RD; Carson WH; Kostic D; Hardy S; Marcus R
    J Clin Psychiatry; 2005 Nov; 66(11):1362-6. PubMed ID: 16420071
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosis.
    Park JI; Cho DH; Hahn SW; Jeong B; Kim JH; Kim SW; Koo MS; Lee SH; Lee SJ; Lee YH; Park JI; Rho SH; Chung YC
    Int Clin Psychopharmacol; 2014 Mar; 29(2):77-85. PubMed ID: 23970176
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole.
    Lu ML; Shen WW; Chen CH
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1978-81. PubMed ID: 18848860
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness of switching to aripiprazole from atypical antipsychotics in patients with schizophrenia.
    Kim SW; Shin IS; Kim JM; Lee JH; Lee YH; Yang SJ; Yoon JS
    Clin Neuropharmacol; 2009; 32(5):243-9. PubMed ID: 19620849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aripiprazole in children and adolescents with conduct disorder: a single-center, open-label study.
    Ercan ES; Uysal T; Ercan E; Akyol Ardic U
    Pharmacopsychiatry; 2012 Jan; 45(1):13-9. PubMed ID: 21993869
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Patients with schizophrenia treated with aripiprazole, a multicentre naturalistic study.
    Christensen AF; Poulsen J; Nielsen CT; Bork B; Christensen A; Christensen M
    Acta Psychiatr Scand; 2006 Feb; 113(2):148-53. PubMed ID: 16423167
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of adjunctive treatment with aripiprazole to atypical antipsychotics on cognitive function in schizophrenia patients.
    Yasui-Furukori N; Kaneda A; Sugawara N; Tomita T; Kaneko S
    J Psychopharmacol; 2012 Jun; 26(6):806-12. PubMed ID: 21616975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia.
    Findling RL; Robb A; Nyilas M; Forbes RA; Jin N; Ivanova S; Marcus R; McQuade RD; Iwamoto T; Carson WH
    Am J Psychiatry; 2008 Nov; 165(11):1432-41. PubMed ID: 18765484
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Worsened agitation and confusion in schizophrenia subsequent to high-dose aripiprazole.
    Thone J
    J Neuropsychiatry Clin Neurosci; 2007; 19(4):481-2. PubMed ID: 18070865
    [No Abstract]   [Full Text] [Related]  

  • 40. Aripiprazole for the treatment of schizophrenia with co-occurring social anxiety: an open-label cross-taper study.
    Stern RG; Petti TA; Bopp K; Tobia A
    J Clin Psychopharmacol; 2009 Jun; 29(3):206-9. PubMed ID: 19440071
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.